Given the limitations associated with our study, related mainly to the small sample size, incomplete clinical and pathological patients’ data and the heterogeneity of the disease, the present study highlights the importance of SPP1 as a valuable prognosticator and potential molecular target for bladder cancer therapy. This evidence concerns the gene SPP1 and urinary bladder cancer.